NATALIZUMAB belongs to the class of monoclonal antibodies. It is used in the treatment of multiple sclerosis (a condition in which the immune system attacks the protective covering of the nerves called myelin, causing disrupted communication between the brain and body) and moderately to severe Crohn’s disease (a chronic bowel disease that affects any part of the gastrointestinal tract, mainly small and large intestine) in patients who are unable to tolerate conventional Crohn’s disease therapy and inhibitors of TNF-α.
NATALIZUMAB consists of Natalizumab, which belongs to the class of integrin receptor antagonists. It works by binding to the chemical substance called α4β7 integrin (present on the surface of the WBC that enters the gut), which is responsible for inflammation.
NATALIZUMAB may cause certain side effects, such as nausea, headache, fever, joint pain, upper respiratory tract infections, abdominal discomfort, diarrhoea, tiredness, back pain, itching, depression, and injection site reactions. Most of these side effects do not require medical attention. However, if these side effects persist, please consult your doctor. NATALIZUMAB will be administered by a trained healthcare doctor. Hence, do not self-administer.
NATALIZUMAB should be avoided if you are allergic to any of its components. Inform your doctor if you have any history of serious infections, tuberculosis, liver or kidney diseases, or a weak immune system, as it can worsen your health condition. NATALIZUMAB is contraindicated in patients with Progressive Multifocal Leukoencephalopathy (PML), as it can cause serious adverse effects. Consult the doctor if you are pregnant or breastfeeding.
Multiple sclerosis, Crohn’s disease.
NATALIZUMAB consists of Natalizumab, which belongs to the class of integrin receptor antagonists. It works by binding to the chemical substance called α4β7 integrin (present on the surface of the WBC that enters the gut), which is responsible for inflammation. This causes inhibition and alters the gene expression of blood monocytes and thus helps reduce inflammation of the bowel disease. It is used in the treatment of moderately to severe Crohn’s disease and multiple sclerosis.
Inform your doctor if you have any history of serious infections, tuberculosis, liver, or kidney diseases, or a weak immune system, as it can worsen your health condition. This medicine is contraindicated in patients with leukemia or lymphoma, or an organ transplant as it can cause life-threatening conditions. NATALIZUMAB may cause serious reactions including infusion-related or allergic reactions. This medicine may also increase the risk of serious infections and hypersensitivity reactions in some patients. Hence, patients should be carefully monitored for any changes during and after the treatment course. NATALIZUMAB is not recommended for use in children below 18 years of age as safety and efficacy are not established. This medicine can cause Progressive Multifocal Leukoencephalopathy (PML) in most patients with compromised immune system. The chance of getting PML is more if the patient is exposed to John Cunningham Virus, if received NATALIZUMAB for longer than 2 years or treated with other medicine that weakens your immune system. Hence it is important to inform your doctor about your complete medication history and previous medical history before receiving NATALIZUMAB.
Drug-Drug Interactions: NATALIZUMAB may interact with immunosuppressants (infliximab, etanercept, adalimumab, golimumab, cyclosporine, glatiramer, interferon beta), anti-cancer drugs (doxorubicin, epirubicin, idarubicin, mercaptopurine), steroid medicines (methylprednisolone, prednisolone, dexamethasone, prednisone), etc.
Drug-Food Interactions: Avoid alcohol consumption and smoking.
Drug-Disease Interactions: NATALIZUMAB should be used with caution in patients with liver or kidney disease, weak immune system, and serious infections.
It is unknown whether alcohol interacts with NATALIZUMAB. Consult your doctor for any concerns regarding this.
If you are pregnant or planning pregnancy, inform your doctor before receiving NATALIZUMAB. Your doctor may prescribe this medicine if the benefits outweigh the risks.
NATALIZUMAB is known to pass in the breastmilk. Hence, if you are breastfeeding, inform your doctor before receiving NATALIZUMAB. Your doctor may administer this medicine only if the benefits outweigh the risks.
-
NATALIZUMAB is known to cause hepatotoxicity in some patients. Hence, caution should be exercised. Inform your doctor if you observe any symptoms of tiredness, loss of appetite, dark urine, yellowing of the skin and eyes, or pain in the abdomen. Dose adjustment may be needed in patients with liver impairment.
NATALIZUMAB should be used with caution if you have kidney disease. Dose adjustment may be needed in patients with liver impairment.
NATALIZUMAB is not recommended in children below 18 years of age as the safety and efficacy are not established.
Multiple sclerosis: Multiple sclerosis is a condition that affects the brain and spinal cord. The immune system attacks the protective covering of the nerves (myelin) and causes disrupted communication between the brain and body due to nerve damage. This causes symptoms such as problems with sensation, balance, vision, pain, impaired coordination, and fatigue.
Crohn’s disease: Crohn’s disease is a type of chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, from mouth to anus. But mostly occurs in the small intestine and large intestine. The symptoms include blood in stools, stomach cramps, tiredness, diarrhoea, fever, weight loss, or loss of appetite.